SYDNEY, AUSTRALIA: ALS Limited has bought an initial 49% shares in NUVISAN, a pharmaceutical testing business with operations in Germany and France, a news release said. ALS will initially acquire 49% of the equity in NUVISAN for consideration of EUR145 million. There is an exclusive ‘call’ option to acquire the remaining equity from 1 January…